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Objective: The receptor for advanced glycation end products (RAGE) is expressed at high levels in the lung,
particularly in type 1 alveolar cells, and has been shown to amplify injury triggered by acute stress. Previous stud-
ies suggest serum concentrations of soluble RAGE increase during pulmonary reperfusion injury after transplan-
tation. RAGE blockade has been shown to suppress hepatic and cardiac ischemia and reperfusion injury in mice.
Thus we tested the hypothesis that RAGE mediates tissue-injury mechanisms in ischemia and reperfusion injury
in the lung.
Methods: C57BL/6 mice were subjected to 30 minutes of pulmonary ischemia by clamping the left hilum, fol-
lowed by 60 minutes of reperfusion. Lung function was assessed by means of blood gas analysis, and capillary
leak was assessed by injecting fluorescein isothiocyanate–labeled albumin and comparing fluorescence in bron-
chial lavage fluid with that in serum. Histologic analysis of the lung was performed by a pathologist naive to the
experimental conditions.
Results: In animals subjected to RAGE blockade, significant increases in PO2 (108 vs 73 mm Hg, P¼ .0094) and
more than 3-fold decrease in capillary leak Relative Fluorescent Units (RFU, 6.12 vs 1.75; P ¼ .001) were ob-
served. Histologic examination revealed significant injury reduction in soluble RAGE-treated animals versus con-
trol animals. RAGE knockout mice exhibited a protected phenotype when exposed to pulmonary ischemia and
reperfusion. Additionally, interleukin 8 production and nuclear factor kB activation were increased in control
mice.
Conclusion: Abrogation of RAGE signaling attenuates pulmonary ischemia and reperfusion injury. This study
suggests that RAGE might play a central role in pulmonary reperfusion injury and in transplantation and that
blockade of RAGE might offer a potential target to abrogate pulmonary reperfusion injury in clinical transplan-
tation.Primary graft dysfunction (PGD) represents a significant
source of postoperative morbidity after lung transplanta-
tion.1 It is the most common cause of early death after trans-
plantation and, when diagnosed in severe forms, strongly
correlates with increased duration of mechanical ventilation,
as well as both intensive care unit and hospital lengths of
stay.2-4 Patients who have severe PGD are more likely to
have diminished forced expiratory volume in 1 second
values and functional capacity and reduced overall rejec-
tion-free and total survival.5,6 Strong evidence suggests
a direct relationship between pulmonary ischemia and reper-
fusion injury (IR) and PGD.3,7-12 Therefore pathways that
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signals are putative targets of therapeutic interest.
The receptor for advanced glycation end products
(RAGE) is both a marker of type 1 alveolar epithelial cell in-
jury and a key early regulator of inflammation.13-15 RAGE is
a multiligand, immunoglobulin-type transmembrane recep-
tor. Under basal conditions, RAGE is expressed at low levels
on a range of cell types but at much higher levels on the ba-
solateral surface of type 1 alveolar epithelial cells.16-19
RAGE plays critical regulatory roles early in inflammatory
signaling cascades that lead to endothelial dysfunction, cap-
illary permeability, and vascular inflammation. Recent work
has elucidated a possible link between RAGE and pulmo-
nary IR. Human lungs with diminished airway fluid clear-
ance are reported to have increased perfusate levels of
soluble RAGE (sRAGE) on an ex vivo preservation cir-
cuit.20 Serum and lavage concentrations of sRAGE are in-
creased during acid and lipopolysaccharide-induced lung
injury in the rat.13 Additionally, lung transplant recipients
with higher serum concentrations of sRAGE are more likely
to have increased duration of mechanical ventilation and
length of stay in the intensive care unit.13,21
However, little is known about the status of the RAGE
signaling axis, its role, and its overall importance inrgery c December 2008
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ELISA ¼ enzyme-linked immunosorbent assay
HMGB1 ¼ high-mobility group box-1
IR ¼ ischemia and reperfusion injury
MG ¼ methylglyoxal
NF ¼ nuclear factor
PCR ¼ polymerase chain reaction
PGD ¼ primary graft dysfunction
RAGE ¼ receptor for advanced glycation end
products
sRAGE ¼ soluble receptor for advanced glycation
end products
pulmonary IR. We therefore hypothesized that the RAGE
pathway could have functional importance in this system.
In this article we report our efforts to characterize the biol-
ogy of the RAGE axis in a murine model of pulmonary is-
chemia and reperfusion and to determine its importance by
antagonizing RAGE signaling and by analysis of RAGE-
deficient mice.
MATERIALS AND METHODS
Animal Model
Approximately 8- to 10-week-old C57BL6J male mice (Jackson Labs,
Bar Harbor, Me) were divided into 4 groups: group 1, sham-treated group
(negative control); group 2, vehicle saline–treated group (positive control);
group 3, soluble RAGE-treated group (experimental group); and group 4,
RAGE-null group. Group 1 sham animals underwent tracheostomy and bi-
lateral thoracotomy but no ischemia or reperfusion. After thoracotomy,
blood gas, lavage, serum, and tissue samples were obtained as the animal
was killed. Group 2 (vehicle saline-injected positive control), group 3
(sRAGE-treated experimental group), and group 4 (RAGE-null group) an-
imals underwent ischemia and reperfusion, as described below. Only group
3 animals received a preoperative injection of sRAGE. Group 2 (vehicle sa-
line) and group 4 (RAGE null) animals underwent preoperative injection of
vehicle saline.
sRAGE is a ligand decoy that traps putative molecules with a suitable
epitope, such as members of the advanced glycation end product (AGE)
family, and prevents interaction with the receptor, thus blocking RAGE sig-
naling. sRAGE was prepared in a baculovirus expression system with Sf9
cells (Clontech, Palo Alto, Calif). The final material was purified to homo-
geneity and devoid of lipopolysaccharide, as previously described.22
RAGE-null mice were used for functional studies, including blood gas
and capillary leak analysis. RAGE-null mice were backcrossed onto the
C57Bl/6 background and exhibit normal reproductive capacity, physical fit-
ness, and overall phenotype under nominal conditions but attenuated RAGE
signaling when vascular inflammation is induced.23
One hour before the operation, the indicated animals received an intra-
peritoneal injection of 100 mg of sRAGE in 0.1 mL of PBS or an equivalent
volume of vehicle saline. Approximately 15 minutes before incision, each
animal received 20 U of subcutaneous heparin in 1 mL of PBS. Induction
of anesthesia was achieved with buprenorphine (0.05 mg/kg) and 3% iso-
flurane delivered through a nose cone and maintained with 1% to 2.5% iso-
flurane and verified by means of tail pinch every 15 minutes. After shaving
and prepping each animal with ethyl alcohol, a tracheostomy was per-
formed, and each animal was placed on a Harvard Mouse VentilatorThe Journal of Thoracic and Ca(Harvard Biosciences, Holliston, Mass) through a 20-gauge angiocatheter
(respiratory rate, 120 beats/min; fraction of inspired oxygen, 0.21; tidal vol-
ume, 0.5 mL). Bilateral anterolateral thoracotomies were performed through
the fourth intercostal space, and the chest wall was retracted with 4-0 silk
stay sutures. The left pulmonary hilum was then crossclamped, and the tidal
volume was reduced to 0.25 mL for a 30-minute period. After the period of
warm ischemia elapsed, the clamp was removed, ventilation with 0.5 mL/
breath resumed, and an additional 1 mL of warmed PBS was delivered
into the peritoneal cavity immediately and then every 60 minutes. After
a 60- or 120-minute period of reperfusion, terminal phlebotomy of arterial
blood from the left ventricle was performed for immediate analysis with
the iSTAT blood gas analyzer (Abbott, East Windsor, NJ). The periods of
ischemia and reperfusion were sometimes extended to suit experimental
conditions or to confirm experimental findings. For example, this was
done for histologic analyses in which more significant injury was needed.
The entire left lung was then either flash-frozen in liquid nitrogen for bio-
chemical analysis or insufflated with 20 cm of column pressure and fixed
with 10% formaldehyde for histologic analysis.
Capillary Leak
Pulmonary edema is assessed by measuring leak of fluorescein isothio-
cyanate–labeled albumin into the lungs normalized against fluorescent ac-
tivity in serum. Briefly, 0.15 mg of fluorescein isothiocyanate–labeled
albumin was injected into the tail vein 1 hour before the operation. After
blood gas analysis, 0.5 mL of blood was withdrawn from the left ventricle.
Both lungs were lavaged with 2 mL of PBS in 1-mL aliquots. Fluorescent
activity of lavage fluid is normalized against diluted serum from each animal
with a Bio-Rad Fluorimeter (Bio-Rad, Hercules Calif).
Real-time Polymerase Chain Reaction (RAGE and
Interleukin 8)
Total RNA from 30 mg of lung tissue was extracted with the Qiagen
RNeasy Mini Kit (Qiagen, Inc, Valencia, Calif), according to the manufac-
turer’s protocol. Reverse transcription was performed with the use of the
High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, Calif).
The reactions were carried out in a volume of 100 mL containing approxi-
mately 15mg of RNA. The resulting cDNA was used as a template in the sub-
sequent polymerase chain reaction (PCR). Expression levels for RAGE and
interleukin 8 were quantified by means of real-time PCR, which was per-
formed with the ABI Prism 7900HT Sequence Detection System (Applied
Biosystems). The reactions were performed in a total volume of 20 mL con-
taining 1mL of the prepared cDNA template, 10mL of 23Taqman Universal
Master Mix (Applied Biosystems), and 1mL of 203 solution containing spe-
cific primers and probe. Each sample was run in triplicate. b-Actin was used
as the housekeeping gene. The data were quantified by using the compara-
tive Ct method that reported the expressions relative to 3 sham samples in-
cluded as housekeeping controls in each real-time PCR experiment.
Western Blotting (RAGE, S100, and High-mobility
Group Box-1)
Lung samples were homogenized in equal volumes of cell lysis buffer
(Cell Signaling, Danvers, Mass) on ice. After 3 cycles of sonication and cen-
trifugation, the cell lysate was separated on a 10% acrylamide gel at 100 V
and transferred to a nitrocellulose membrane in standard fashion. The
membranes was then washed, blocked (5% bovine serum albumin or
milk, Tris-buffered 0.1% triton containing saline solution) and then incu-
bated with either goat anti-mouse RAGE, rabbit anti-mouse S100 (Abcam,
Cambridge, Mass), or rabbit anti-mouse high-mobility group box-1
(HMGB1) IgGs (BD PharMingen, Franklin Lakes, NJ) per the manufac-
turer’s protocol. The membranes were washed again, labeled with horserad-
ish peroxidase–labeled secondary antibody in blocking solution, developed
in a chemiluminescent detection kit (Pierce, Rockford, Ill), and exposed on
Kodak film (Rochester, NY).rdiovascular Surgery c Volume 136, Number 6 1577
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For histologic analysis, all animals underwent an extended 60-minute pe-
riod of warm ischemia, followed by an extended 120 minutes of reperfusion.
This was done to amplify the degree of injury to suit the experimental con-
ditions needed for histologic analyses. The animals were closely monitored,
volume resuscitated every 60 minutes with 1 mL of warmed intraperitoneal
saline, and censored from the study if premature cardiac arrest was encoun-
tered. After the 120-minute reperfusion period was complete, the lungs were
excised, insufflated with 20 cm of column pressure of 10% formaldehyde,
and fixed. After routine histologic processing in paraffin blocks, hematoxy-
lin and eosin–stained sections were prepared and then scored by a blinded
pathologist in 4 categories on a scale of 0 (no injury) to 4 (most severe in-
jury): capillary congestion, hemorrhage, edema, and inflammation. After
scoring was complete, the total numeric score was tabulated by summing
all categories for each specimen, and the scores were then tested for signif-
icance by means of analysis of variance.
Methylglyoxal
Methylglyoxal (MG) was measured in the neutralized perchloric acid ex-
tracts of hearts by means of high-performance liquid chromatographic
methods, according to previously published procedures.24,25
Nuclear Factor kB and KC Enzyme-linked
Immunosorbent Assay
Nuclear protein was extracted from 40 mg of lung tissue by using the
Pierce NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Bio-
technology). Nuclear factor (NF) kB activity was then determined in the nu-
clear protein by using the TransAM NF-kB enzyme-linked immunosorbent
assay (ELISA) kit (Active Motif, Carlsbad, Calif), according to the manu-
facturer’s protocol, with approximately 12 mg of nuclear extract per well.
The concentration of mouse KC was determined in the protein samples
by using the Quantikine Mouse KC kit (R&D Systems, Minneapolis, Minn),
according to the manufacturer’s protocol. Approximately 40 mg of total pro-
tein, prepared as directed by manufacturer protocol, was used per well. Both
the NF-kB and KC ELISA kits were then scored on a Tecan Sunrise Plate
Spectrophotometer (Tecan Co, Durham, NC).
Statistical Methods
In all cases the mean  standard error of the mean is shown. A 1-way
analysis of variance was performed to analyze the results of all the experi-
ments. If the F test resulted in a P value of less than .05, multiple compar-
isons were made by means of Tukey’s pairwise testing, which conserves the
overall type I error of .05. All data were analyzed with SAS system software
(SAS Institute, Inc, Cary, NC).
Ethical Guidelines
All animals were housed, cared for, and treated in compliance with
guidelines stipulated in the ‘‘Guide for the care and use of laboratory ani-
mals’’ and by the Institutional Animal Care and Use Committee, which ap-
proved and supervised this project. Funding agencies did not participate in
data analysis or manuscript preparation.
RESULTS
RAGE and Its Ligands in Pulmonary IR
Expression of RAGE mRNA transcripts in lung tissue
was assessed through real-time PCR after 30 minutes of is-
chemia and 60 minutes of reperfusion (Figure 1, A). Com-
pared with sham-treated animals, an approximately 45%
reduction in RAGE transcripts was observed in animals
undergoing IR in the presence of vehicle (P ¼ .03), and an1578 The Journal of Thoracic and Cardiovascular Sapproximately 64% reduction in sRAGE-treated animals
was seen compared with that seen in sham-treated animals
(P ¼ .001). In parallel with these changes in RAGE tran-
scripts, expression of RAGE protein, as determined after
30 minutes of ischemia and 60 minutes of reperfusion
through Western blot analysis, revealed an approximately
27% reduction of RAGE protein in vehicle-treated animals
(P ¼ .02) and an approximately 52% reduction in levels in
sRAGE-treated animals after reperfusion compared with
that seen in the sham-treated group (P ¼ .0001; Figure 1,
B and C). Trends observed between the sRAGE- and vehi-
cle-treated groups that underwent surgical intervention did
not reach statistical significance at the transcript (P ¼ .19)
or protein (P ¼ .31) level.
To further assess the status of the RAGE axis, we tested
the levels of the RAGE ligands. We first analyzed the
AGE axis and focused on measurement of MG, a key pre-
AGE and a highly cytotoxic a-oxoaldehyde, the production
of which is enhanced by hyperglycemia, inflammatory in-
jury, and severe oxidative stress (Figure 1, D).26 MG is
highly reactive with proteins and leads to the formation of
multiple AGEs, which stimulate and upregulate the RAGE
pathway.27,28 We measured MG levels in the lung tissue
both after 30 minutes of ischemia and again after 60 minutes
of reperfusion. MG levels were significantly increased in
lung homogenates of control vehicle–treated animals under-
going IR compared with those seen in sRAGE–treated ani-
mals or sham-treated animals after ischemia (11.6 vs 3.6
mg/mL, P ¼ .04). However, no differences in MG levels
were seen after reperfusion (data not shown).
Members of the S100/calgranulin proteins are intracellu-
lar calcium-binding proteins that are released by cells,
such as stimulated macrophages, leukocytes, and lympho-
cytes, where they can bind RAGE, inducing RAGE signal-
ing in an autocrine or paracrine manner.29 Increased levels
of neutrophil-derived S100 have also been detected in pul-
monary lavage fluid and lung parenchyma during acute
lung injury.30 Amphoterin/HMGB1 is an intracellular
DNA binding protein that is secreted by stimulated cells,
such as macrophages, and also binds and upregulates the
RAGE axis.31 We therefore measured both S100 (Figure 1,
E and F) and HMGB1 (Figure 1, G and H) protein levels by
means of Western blotting after 30 minutes of ischemia and
60 minutes of reperfusion injury. Compared with sham ani-
mals, there were no significant differences in levels of S100
or HMGB1 in vehicle- or sRAGE-treated mice (P> .5).
Functional Studies
To test the potential effect of RAGE blockade on the func-
tional capacity of the lungs, we used multiple methodolo-
gies. First, blood oxygen concentration was determined by
means of routine arterial blood gas analysis performed on
left ventricular blood immediately after reperfusion. Ani-
mals undergoing sham operations displayed a mean PO2 ofurgery c December 2008
Sternberg et al Cardiothoracic Transplantation
T
XThe Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 6 1579
Cardiothoracic Transplantation Sternberg et al
T
Xapproximately 137  5 mm Hg. After 30 minutes of ische-
mia and 60 minutes of reperfusion, the PO2 in vehicle-treated
animals (73  8 mm Hg) was significantly lower than that
seen in sRAGE-treated animals (108  9 mm Hg, P ¼
.0094) or RAGE-null mice (109 7 mm Hg, P¼ .003; Fig-
ure 2, A). Oxygenation was also evaluated after 30 minutes
of ischemia, with reperfusion extended to 120 minutes. The
PO2 in vehicle-treated animals after 120 minutes (66 9 mm
Hg) was significantly lower than that seen in sRAGE-treated
mice (94  8 mm Hg, P ¼ .003; Figure 2, B). Furthermore,
we extended ischemia to 60 minutes and reperfusion to 120
minutes and remeasured oxygenation. Vehicle-treated ani-
mals exhibited a lower mean PO2 (56 6 mm Hg) compared
with sRAGE-treated animals (102  8 mm Hg, P ¼ .0001).
The blood gases for each experimental group are shown in
Table 1. Significant differences were only observed for
PO2 and oxygen saturation but not for pH, PCO2, or HCO3
levels.
Pathologic analyses have established vascular permeabil-
ity as a central characteristic finding of acute lung injury. We
evaluated the protein permeability of the respiratory mem-
brane by injecting fluorescein-labeled albumin into the tail
vein before surgical intervention and then measuring the
fluorescent intensity of alveolar lavage fluid normalized to
serum (Figure 2, C). After 30 minutes of ischemia and 60
minutes of reperfusion, alveolar lavage fluorescent intensity
was approximately 6.1-fold higher in vehicle-treated ani-
mals but only approximately 1.7-fold higher in sRAGE-
treated animals compared with that seen in mice subjected
to sham operations (P<.001). Measurement of lavage fluo-
rescent intensity after 30 minutes of ischemia and 120 min-
utes of reperfusion demonstrated significantly higher levels
in vehicle-treated animals (approximately 4.9-fold) than
seen in sRAGE-treated animals (approximately 1.9-fold,
P ¼ .03) or RAGE-null mice (approximately 1.5-fold, P ¼
.02; Figure 2, D).
Histology
Hematoxylin and eosin–prepared specimens were pre-
pared from murine lungs after 60 minutes of ischemia and
120 minutes of reperfusion (Figure 3, A). Each specimen
was scored from 0 (no injury) to 4 (most severe injury) on
each of 4 axes, as described above. Vehicle-treated animals
demonstrated significantly greater histologic injury (mean
score, 6.3) versus that seen in sRAGE-treated animals
(mean score, 4.8; P¼ .01), RAGE-null animals (mean score,
5.2; P¼ .03), or sham-treated animals (mean score, 4.5; P¼
.007). Figure 3, B and C, shows representative sections from1580 The Journal of Thoracic and Cardiovascular SusRAGE- and vehicle saline–treated mice after 60 minutes of
ischemia and 120 minutes of reperfusion.
Interleukin 8 and KC protein
Interleukin 8, a proinflammatory cytokine with a profound
chemotactic effect on neutrophils, is a marker of pulmonary
reperfusion injury.32 Increased posttransplantation levels of
interleukin 8 correlate well with poor oxygenation, increased
airway pressures, decreased APACHE scores, and decreased
patient survival.32 We therefore measured interleukin 8,
transcripts as well the murine protein homolog of interleukin
8, KC protein, in our model of reperfusion injury with and
without sRAGE antagonism (Figure 4).33,34 After 30 min-
utes of ischemia and 60 minutes of reperfusion, vehicle-
treated animals displayed approximately 31.5 times higher
interleukin 8 transcripts than sham-treated animals. In con-
trast, sRAGE-treated animals exhibited only a 13.8-fold in-
crease (P ¼ .02). Analysis of KC protein content by means
of ELISA in lung homogenates demonstrated a statistically
significant increase in vehicle-treated animals (444.5 pg/
mL) compared with that seen in sRAGE-treated mice
(171.5 pg/mL, P ¼ .02) or sham-treated animals (43.7 pg/
mL, P ¼ .008).
NF-kB
NF-kB is a ubiquitous transcription factor that is activated
by a large variety of stimuli, including hypoxia and ische-
mia. When activated, subunits of NF-kB relocate into the
nucleus and upregulate a variety of genes that together coor-
dinate the inflammatory response.35 Previous studies
revealed that inhibition of NF-kB activation and nuclear
localization have been shown to attenuate the severity of
pulmonary reperfusion injury in a porcine model.36 Thus
to discern the potential effect of RAGE on NF-kB activation
in this murine model, we measured activated NF-kB in nu-
clear preparations of lung homogenates after 30 minutes of
ischemia and 60 minutes of reperfusion. An increase in acti-
vated NF-kB levels was observed in vehicle-treated animals
compared with that seen in the sRAGE-treated (P¼ .004) or
sham-treated (P ¼ .01) groups (Figure 5).
DISCUSSION
In human subjects PGD is characterized by endothelial
dysfunction, loss of the alveolar boundary, and leukocytic
infiltration.20,37,38 Strong evidence suggests the inciting
event for this process occurs during pulmonary reperfu-
sion.3,7-12 An activated and dysfunctional pulmonary endo-
thelial surface promotes platelet margination, sequestration,FIGURE 1. Left lung tissue was retrieved at the indicated time points and prepared for analyses. A, Real-time polymerase chain reaction analysis of receptor
for advanced glycation end products (RAGE) transcript after reperfusion injury (n ¼ 8). B and C, Western blot analysis of RAGE protein after ischemia and
reperfusion (n ¼ 9). D, Methylglyoxal concentration after 30 minutes of ischemia (n ¼ 5). E and F, Western blot analysis of S100 (n ¼ 6, P>.5). G and H,
Western blot analysis of high-mobility group box-1 (HMG1; n¼ 6, P>.5). sRAGE, Soluble receptor for advanced glycation end products; I/R, ischemia and
reperfusion injury.rgery c December 2008
Sternberg et al Cardiothoracic TransplantationFIGURE 2. Analyses of pulmonary function. A and B, Oxygenation is measured after reperfusion by means of blood gas analysis at 2 time points:
60 minutes (n ¼ 13) and 120 minutes (n ¼ 17). C and D, Capillary leak data were measured after 60 minutes (n ¼ 7) and 120 minutes of reperfusion
(n ¼ 7). RAGE, Receptor for advanced glycation end products; sRAGE, soluble receptor for advanced glycation end products; I/R, ischemia and re-
perfusion injury.T
Xand stimulation of complement activation, thus exacerbating
local tissue injury caused by hypoxia, cold storage, and later
reactive oxygen metabolites.39-44 Recruited neutrophils re-
lease TNF-a, as well as other chemokines, and contribute
to a more sustained injury that is thought to peak several
hours after reperfusion commences.45,46 A local proinflam-
matory state, similar to that of acute respiratory distress syn-
TABLE 1. Arterial Blood Gas Analysis
pH PCO2 PO2 HCO3

Oxygen
saturation
Sham 7.35  0.03 28.3  3.1 137  5 14.5  0.8 99  0.1
Vehicle
saline
7.32  0.03 31.4  4.0 73  8 15.4  1.0 90  3
sRAGE
treated
7.30  0.02 30.7  2.3 108  9 15  0.6 96  1.5
RAGE null 7.34  0.03 25.2  3.4 109  7 14.5  1.1 96  1.1
P value .65 .53 <.001 .86 .03
sRAGE, Soluble receptor for advanced glycation end products; RAGE, receptor for ad-
vanced glycation end products.The Journal of Thoracic and Cadrome, is achieved that causes type 1 alveolar epithelial cell
dysfunction and results in diminished alveolar space fluid
clearance.20
RAGE is both a marker of type I alveolar epithelial cell
injury and a key early regulator of inflammation.13-15
RAGE is a multiligand, immunoglobulin-type transmem-
brane receptor that is widely expressed on endothelial and
inflammatory cell surfaces and at particularly high concen-
trations on the basolateral surface of type 1 alveolar
cells.16-19 RAGE plays a critical role in inflammatory cas-
cades that lead to endothelial dysfunction and capillary per-
meability. The first RAGE ligand families include AGEs, the
products of nonenzymatic glycation and oxidation of pro-
teins that accumulate during diabetes, aging, renal failure,
oxidative stress, and neurodegeneration. RAGE was also
found to be a signal transduction receptor for S100/calgranu-
lins and HMGB1 ligands, which are proinflammatory
cytokines secreted by activated macrophages.29,31,47,48
RAGE–ligand interaction can stimulate diverse signalingrdiovascular Surgery c Volume 136, Number 6 1581
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along 4 categories (capillary congestion, hemorrhage, edema, and inflammation) after 60 minutes of ischemia and 120 minutes of reperfusion. Scores were
then summed for each animal (n¼ 8). B and C, Representative hematoxylin and eosin (H& E; original magnification 203) stain of vehicle saline–treated (B)
and soluble receptor for advanced glycation end products (sRAGE)–treated (C) lung demonstrating increased edema and inflammatory response after 60 min-
utes of ischemia and 120 minutes of reperfusion. I/R, Ischemia and reperfusion injury.pathways, such as Janus kinase/signal transducer and activa-
tor of transcription, p44/p42, p38, SAP/c-Jun N-terminal ki-
nase, and mitogen-activated protein kinases, and yield
nuclear localization of NF-kB and thereby proinflammatory
phenotypes.49-52
In this article we have shown that pharmacologic antago-
nism or genetic deletion of RAGE attenuates pulmonary re-
perfusion injury in a murine model. We have shown that
oxygenation, capillary leakage, and histologic injury all im-
proved in animals pretreated with the RAGE ligand decoy
sRAGE. RAGE was a critical target of ligand-mediated in-
jury because RAGE-null mice also did not have pulmonary
reperfusion injury. Previous reports have suggested RAGE
involvement in IR because lavage and serum levels of
sRAGE were increased in this setting and because concen-
tration correlated with clinical outcome. However, to our
knowledge, this is the first report that functional blockade
of the RAGE axis attenuates or prevents reperfusion injury,
thus establishing the RAGE pathway as important in the de-
velopment of reperfusion injury.
We also studied the biology of the RAGE axis in a murine
model of reperfusion injury. We were surprised to discover1582 The Journal of Thoracic and Cardiovascular Sudecreased quantities of RAGE transcript and protein because
RAGE is typically upregulated at sites of chronic inflamma-
tory injury.53 However, these findings might highlight spe-
cific and unique aspects of the biology of RAGE in the
lung. For example, RAGE is normally expressed at low
levels in most organs and upregulated during inflammatory
injury. In the lung, in contrast, baseline RAGE expression
increases with age from birth to high levels in adulthood
and might be downregulated in response to certain specific
stimuli.17,54,55 For example, exposure to hyperoxic atmo-
spheres causes downregulation of pulmonary RAGE in the
rat.55 Additionally downregulation of RAGE protein sup-
ports the growth and metastasis of pulmonary carcinoma.56
Other reports, however, suggest upregulation of RAGE
might occur in response to inflammatory stimuli in the
lung, such as exposure to cigarette smoke or chronic pneu-
monia.57 One possibility is that these diverse injuries cause
severe damage and/or loss of the RAGE-expressing type 1
alveolar epithelial cells. Alternatively, these injuries might
stimulate diverse changes in gene expression in these cells,
including downregulation of RAGE. Because the reports
all use different models of lung injury (eg, cigarette smoke,rgery c December 2008
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protein regulation during pulmonary injury might not be
possible at this time. Scrutiny of the concentration of
sRAGE in various disease states has also not been consistent
to date.58 A variety of reports document increases in sRAGE
concentrations in diabetic vasculopathy, chronic kidney dis-
ease, and acid-injured lungs.13,59,60 Other reports, however,
suggest a decreased concentration of sRAGE in hyperten-
sion, Alzheimer’s disease, and coronary artery disease.61-63
Because the disease states and respective mechanisms vary
significantly, it is perhaps too early to draw clear conclusions.
Clearly, the biology of the RAGE axis in the lung is complex
and warrants further investigation.
MG is a highly reactive metabolite that is formed by con-
ditions created by high oxidative stress and catalyzes the for-
mation of AGEs.64 Although the tissue MG level is normally
tightly regulated, MG concentrations increased during ische-
mia but rapidly normalized during reperfusion. This is con-
FIGURE 4. Left lung tissue was retrieved at the indicated time points and
prepared for analyses. A, Real-time polymerase chain reaction analysis of
interleukin 8 transcript after 30 minutes of ischemia and 60 minutes of re-
perfusion (n ¼ 9). B, Enzyme-linked immunosorbent assay detection of
KC protein (interleukin 8 murine homologue) after 30 minutes of ischemia
and 60 minutes of reperfusion (n ¼ 10). sRAGE, Soluble receptor for ad-
vanced glycation end products; I/R, ischemia and reperfusion injury.The Journal of Thoracic and Csistent with the highly active pulmonary glyoxalase system,
which rapidly and efficiently disposes of MG, preventing fa-
tal accumulation of this toxic compound. We also investi-
gated 2 distinct proinflammatory RAGE ligands, HMGB1
and S100. Unlike AGEs, in this specific model we were un-
able to detect changes in protein levels of these RAGE li-
gands. However, there are a number of putative AGE
ligands that might be operative during pulmonary reperfu-
sion injury, and further work is needed to identify the spe-
cific molecule or molecules interacting with RAGE during
pulmonary IR.
Interleukin 8 and NF-kB were also studied to determine
the interaction of the RAGE axis with other key modulators
and markers of pulmonary IR. Increased posttransplantation
levels of interleukin 8 correlate well with poor oxygenation,
increased airway pressures, decreased APACHE score, and
decreased patient survival.32 In our model interruption of
RAGE signaling resulted in reduced interleukin 8 transcripts
and its murine protein homolog, KC, when compared with
levels seen in vehicle-treated animals. Concentrations of ac-
tivated NF-kB in nuclear preparations of lung homogenate
were also reduced in sRAGE-treated animals. Increases in
interleukin 8 and nuclear NF-kB levels and histologic injury
suggest that RAGE signaling precedes recruitment of the in-
flammatory infiltrate. This is consistent with the established
role of RAGE in the early amplification of inflammatory
signals.
In summary, we report that RAGE signaling blockade
prevents the development of pulmonary reperfusion injury
in a murine model. The high incidence and often great sever-
ity of pulmonary IR increases morbidity, limits patient sur-
vival, and limits optimal patient outcomes, severely
hampering the wider application of lung transplantation in
patients with end-stage respiratory failure. The absence of
FIGURE 5. Left lung tissue was retrieved at the indicated time points and
prepared for analysis of activated nuclear factor kB. Activated nuclear factor
kB measured by means of enzyme-linked immunosorbent assay in nuclear
preparations after 30 minutes of ischemia and 60 of minutes reperfusion
(n ¼ 11). sRAGE, Soluble receptor for advanced glycation end products;
I/R, ischemia and reperfusion injury.ardiovascular Surgery c Volume 136, Number 6 1583
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Xalternative, clinically viable therapeutic solutions for pa-
tients with end-stage lung disease mandates further work
to elucidate the importance of RAGE signaling in human
pulmonary IR.
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